EUVIMEDEUVIMED entdecken
Crossref

Initial experience with ABO-incompatible living-donor kidney transplantation in Kazakhstan: A single-center feasibility study

Islam Madadov, Dilmurat Akhmetov, Ernur Belgibaev, Elshad Nabiev, Berik Rgebayev, Nursultan Saduakas, Bolatbek Baimakhanov

Transplant Immunology · 2026-08 · 97 · 102410

DOI: 10.1016/j.trim.2026.102410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2026-08. Verfasst von Islam Madadov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kidney Transplantation, A.N. Syzganov National Research Centre of Surgery, Almaty, Kazakhstan. Hauptthemen laut MEDLINE: Kidney Transplantation, ABO Blood-Group System, Blood Group Incompatibility, Graft Rejection. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Ministry of Science and Higher Education of the Republic of Kazakhstan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND ABO-incompatible living-donor kidney transplantation (ABOi-LDKT) expands the donor pool for patients with end-stage renal disease, but outcome data from Central Asia are lacking. We report the first ABOi-LDKT outcomes from this region. METHODS In this retrospective feasibility study, 10 consecutive ABOi-LDKT recipients treated between April 2022 and March 2025 at the A.N. Syzganov National Research Centre of Surgery, Almaty, Kazakhstan, were compared with 30 antithymocyte globulin-induced ABO-compatible controls (ATG-ABOc) matched 1:3 by transplant date, age, and sex. Desensitisation comprised rituximab (375 mg/m2), plasmapheresis (median 4 sessions), and low-dose intravenous immunoglobulin (0.10 g/kg per session). The primary outcomes were patient and graft survival. RESULTS At a median follow-up of 31.5 months (range 18-47), patient survival was 100% in both groups. Two-year graft survival was 88.9% in the ABOi group and 100% in the ABOc group (log-rank p = 0.096); the single graft loss occurred at 15 months because of refractory antibody-mediated rejection (AMR) in a high-risk retransplant recipient. Acute rejection occurred in 2/10 ABOi recipients (20%; both AMR) versus 2/30 ATG-ABOc recipients (7%; both borderline changes). Infectious complications were more frequent in the ABOi group (50% vs 13%; p = 0.029). Estimated glomerular filtration rate was lower in the ABOi group at months 1 and 12. The median desensitisation cost was USD 4560. CONCLUSIONS ABOi-LDKT using a low-dose IVIG-supplemented desensitisation protocol appears feasible in carefully selected patients in Central Asia, although infectious complications remain the principal safety concern. Larger multicentre studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationABO Blood-Group SystemBlood Group IncompatibilityGraft RejectionKidney Failure, ChronicHumansFemaleLiving DonorsKazakhstanAdultMaleMiddle AgedGraft SurvivalFeasibility StudiesRetrospective StudiesDesensitization, ImmunologicImmunoglobulins, IntravenousRituximabPlasmapheresisFollow-Up Studies

Stichwörter der Autor:innen

ABO-incompatibleCentral AsiaDesensitisationGraft survivalIsoagglutininKazakhstanKidney transplantationLiving donorPlasmapheresisRituximab

Substanzen

ABO Blood-Group SystemImmunoglobulins, IntravenousRituximab

Autor:innen und Institutionen

  • Department of Kidney Transplantation, A.N. Syzganov National Research Centre of Surgery, Almaty, Kazakhstan.
  • Department of Kidney Transplantation, A.N. Syzganov National Research Centre of Surgery, Almaty, Kazakhstan. Electronic address: dilmurat96@gmail.com.

Förderung

  • Ministry of Science and Higher Education of the Republic of Kazakhstan

Zitieren

APA

Madadov, I., Akhmetov, D., Belgibaev, E., Nabiev, E., Rgebayev, B., Saduakas, N., & Baimakhanov, B. (2026). Initial experience with ABO-incompatible living-donor kidney transplantation in Kazakhstan: A single-center feasibility study. Transplant Immunology, 97, 102410. https://doi.org/10.1016/j.trim.2026.102410

Vancouver

Madadov I, Akhmetov D, Belgibaev E, Nabiev E, Rgebayev B, Saduakas N, et al. Initial experience with ABO-incompatible living-donor kidney transplantation in Kazakhstan: A single-center feasibility study. Transplant Immunology. 2026;97:102410. doi:10.1016/j.trim.2026.102410

BibTeX
@article{Madadov2026,
  author = {Madadov, Islam and Akhmetov, Dilmurat and Belgibaev, Ernur and Nabiev, Elshad and Rgebayev, Berik and Saduakas, Nursultan and Baimakhanov, Bolatbek},
  title = {Initial experience with ABO-incompatible living-donor kidney transplantation in Kazakhstan: A single-center feasibility study},
  journal = {Transplant Immunology},
  year = {2026},
  volume = {97},
  pages = {102410},
  doi = {10.1016/j.trim.2026.102410}
}
Kostenlos starten →